Christopher Emil WHITEHEAD,Elizabeth ZIEMKE,Judith SEBOLT-LEOPOLD
申请号：
US16347496
公开号：
US20200078360A1
申请日:
2017.11.03
申请国别(地区):
US
年份:
2020
代理人:
摘要：
This invention is in the field of medicinal chemistry. In particular, the invention relates to anew class of small-molecules having a quinazoline structure which function as dual inhibitors EGFR and PI3K, and their use as therapeutics for the treatment of cancer (e.g., cancers associated with mutated KRAS and BRAF) (e.g., in combination with MAPK pathway inhibitors (e.g., BRAF inhibitors, MEK inhibitors, ERK inhibitors).
